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ABSTRACT  
 
Purpose of review: Approximately 50% of all patients with primary CNS lymphoma (PCNSL) 
are 60 years or older and may therefore be considered as elderly. While the diagnostic work-up 
is basically the same in young and in elderly patients, therapeutic strategies vary considerably. 
Here we review characteristics of elderly PCNSL patients with a particular focus on advances in 
the optimization of treatment regimens.  
Recent findings: Age has been repeatedly confirmed as a major therapy-independent negative 
prognostic factor. Benefit from treatment and the tolerability of tumor-specific therapy, 
particularly whole brain radiotherapy, are significantly lower in the elderly. Still, for patients with 
newly diagnosed PCNSL, several studies emphasized the undisputable role of high-dose 
methotrexate as backbone for any therapy regimen also in elderly patients. However, the 
durability of responses to primary chemotherapy is significantly shorter than in young patients. 
Recent data from a randomized phase II study for elderly PCNSL patients suggest that the 
combination of high-dose methotrexate, procarbazine, vincristine and cytarabine is superior to 
methotrexate in combination with temozolomide.  
Summary: Current efforts aim at treating elderly PCNSL within clinical trials which are 
specifically designed for this group of patients. Determining adapted consolidation and/or 
maintenance treatment to improve disease control in responding patients are the main 
challenges to be faced by future trials. Together with a better understanding of age-specific 
changes in the biology of PCNSL, this will pave the road to elderly-tailored therapies.  
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Introduction 
 
Although a rather rare disease, primary CNS lymphoma (PCNSL) has always been a neoplasm 
of particular interest since it is potentially curable which is in sharp contrast to most other 
malignant brain tumors. Approximately 50% of all PCNSL patients are 60 years or older and the 
proportion of elderly patients diagnosed with PCNSL is increasing for unknown reasons [1]. In 
the elderly population, however, cure is much less frequently achieved [2]. It has long been 
recognized that age at diagnosis is one of the strongest negative prognostic factors in PCNSL. 
Most likely, it is not higher age per se, but rather the presence of various co-morbidities in the 
elderly which make these patients more susceptible to treatment-related side effects. 
Furthermore, elderly patients are more likely to be on other medications with a potential of 
pharmacological interactions which can translate into either reduced activity of the tumor-
specific treatment or unwanted side effects [3]. However, it cannot be excluded that the negative 
prognostic value of age partially reflects age-specific alterations in the biology of these tumors 
which contribute to therapy resistance. 
Owing to its strong prognostic impact, all scores aiming at classifying patients into prognostic 
subgroups encompass age as an important parameter. Overall, the term “elderly” remains 
poorly defined and there is no consensus on the optimal cut-off which is typically made at age 
60 or 65. However, particularly between 60 and 70 years, there are considerable inter-individual 
differences in the overall constitution which preclude a definitive cut-off for separation between 
“young” and “elderly”. While the “Memorial Sloan-Kettering Cancer Center prognostic model” 
uses a cut-off even at age 50, the IELSG score divides patients with a cut-off at age 60 [4, 5]. 
Whether the importance of age can be depicted by a single cut-off or whether at least three age 
categories may allow for a more appropriate patient stratification, has not yet been defined. 
Treatment decisions in patients aging from 60 to 70 years should therefore be guided not only 
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by age but by additional criteria summarized by the term “frailty” which involves the overall 
performance status as well as co-morbidities and thus indicates an increased risk of intolerance 
of more intense therapy. 
In general, elderly cancer patients are more likely to develop cognitive impairment as a result of 
tumor-specific therapy [6]. The risk is even higher in patients suffering from PCNSL owing to the 
fact that the tumor resides in the brain which is therefore a direct target of local therapies such 
as whole-brain radiation therapy (WBRT). Not surprisingly, severe neurotoxicity is frequent in 
elderly PCNSL patients treated with WBRT [7]. Similarly, combinatorial approaches including 
WBRT led to profound cognitive impairment [8-10]. However, not only WBRT but also systemic 
therapies increase the risk for the development of cognitive decline. This phenomenon, also 
known as chemobrain, is more common in the elderly [11]. Furthermore, intense treatment 
regimens such as high-dose chemotherapy with subsequent autologous stem cell 
transplantation are restricted to the younger patient population because of their systemic 
toxicity. Accordingly, treatment of PCSNL in the elderly strives for the maintenance of quality of 
life and preservation of functional independence with a particular focus on neurocognitive 
function rather than for cure. 
Age-related molecular genetic characteristics in PCNSL tumor tissue have not been identified 
so far. Hence, an age-dependent frequency and prognostic role of specific gene mutations such 
as isocitrate dehydrogenase (IDH) gene mutations in gliomas has not yet been described in 
PCNSL [12, 13]. It needs to be awaited whether such molecular markers, which may account for 
the negative prognostic impact of age, will become available in the future. However, detailed 
molecular analyses of PCNSL specimens are commonly limited by the available amount of 
tissue, typically obtained by a biopsy-only approach. Still, it might be possible that 
comprehensive analyses of PCNSL samples will be accomplished within the next years. Similar 
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to other brain tumors, such high-throughput-profiling approaches may allow for the detection of 
age-specific alterations which could then be exploited for treatment stratification. 
 
Treatment: general considerations 
Histopathological confirmation of a CNS lymphoma must be followed by a staging evaluation. 
The diagnostic procedures, which primarily aim at excluding the presence of concomitant 
systemic lymphoma, do not differ between young and elderly patients [14]. Upon completion, 
treatment should start as soon as possible to avoid further tumor growth and clinical 
deterioration.  
The role of surgery has been limited for decades to bioptic sampling of tumor tissue which is 
sufficient for a histopathological diagnosis. However, a more recent analysis suggests that 
complete or partial resection of PCNSL translates into prolonged progression-free survival 
(PFS) and overall survival (OS) at least in patients with single brain lesions [15]. Accordingly, 
also in the elderly, tumor resection should be considered when a lymphoma is suspected and 
surgery can be carried out with a manageable risk of postoperative deficits and perioperative 
morbidity. Obviously, this situation will be mainly found in patients who present without severe 
comorbidities with a single and rather superficially located tumor mass. 
Although WBRT may result in high response rates, it typically does not confer long-lasting 
remissions [16]. Furthermore, because of its deleterious effects on the neurocognitive function, 
it has been largely abandoned in elderly patients as first-line treatment. In contrast, high-dose 
MTX (HD-MTX) has become the backbone of any treatment regimen for PCNSL, also in elderly 
patients. The combination of HD-MTX with other chemotherapeutic drugs has resulted in 
increased response rates in young and elderly patients. However, a proof of superiority of these 
combinatorial approaches in terms of prolonging OS is lacking [17]. In contrast, it became clear 
that elderly PCNSL patients are more likely to experience relevant side effects from 
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polychemotherapy. As in young patients, consolidating WBRT does not prolong OS but is 
associated with increased toxicity in elderly patients [18, 19].  Therefore, it remains to be 
determined which drug(s) should be added to HD-MTX. There is no standard of care for elderly 
patients who are definitively ineligible for HD-MTX-based therapy. Treatment with the alkylating 
agent temozolomide alone resulted in low response rates and overall poor survival in elderly 
patients [20]. Here, WBRT may be used as a rescue strategy despite its drawbacks mentioned 
above.  
 
Clinical trials for elderly PCNSL patients 
Elderly patients are frequently underrepresented in clinical trials [21] because such trials had 
upper age limits or elderly patients did not comply with inclusion criteria, e.g. because of co-
morbidities. In contrast to young patients where the diagnosis of PCNSL is typically the only 
severe diagnosis, elderly patients are much more likely to suffer from one or more additional co-
morbidities which preclude intense therapy regimens [22]. Still, the successful completion of 
elderly trials in PCNSL demonstrates that such studies are feasible and enrolment of patients 
into open trials should be encouraged whenever possible.  
HD-MTX doses of at least 3 g/m2 result in sufficient CNS levels that are cytotoxic to lymphoma 
cells [8]. Treatment with HD-MTX can be associated with significant toxicity and some 
physicians are hesitant to use it in elderly patients. However, retrospective series of patients 
treated with HD-MTX monotherapy alone indicate that it is active and can be administered 
safely to elderly patients [23, 24]. The high response rates reported here may result from patient 
selection as well as the retrospective nature of these series and could not be reproduced in 
prospective trials (see below). Reductions of the MTX dose are required more frequently in the 
elderly and should be done based on the glomerular filtration rate (GFR) before each treatment 
cycle. Termination of MTX treatment because of MTX-related toxicity or delayed serum MTX 
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clearance was observed to a similar extent in young and elderly patients when the MTX dose 
was calculated in a GFR-dependent manner [25]. Exceedingly high MTX area under the curve 
(AUC) levels may reduce PFS and OS in elderly patients and should therefore be avoided [26]. 
Nevertheless, a series of patients aged 80 or higher demonstrated that the administration of 
HD-MTX is feasible even in the oldest patients [27].  
Similar to young patients, treatment with HD-MTX alone was considered not active enough and 
several prospective trials, specifically designed for the elderly, aimed at assessing the efficacy 
of HD-MTX in combination with various other compounds (Table 1). The EORTC conducted the 
first multicenter phase II trial devoted to the elderly which evaluated a combination including 
HD-MTX (1g/m2), CCNU, procarbazine and MTX/cytarabine intrathecal chemotherapy without 
WBRT as initial treatment.  A 42% complete response (CR) rate as well as a median PFS and 
OS of 10 months and 14.3  months respectively were reported with an acceptable tolerance and 
good preservation of cognitive function in long-term survivors [28]. Illerhaus et al [29] evaluated 
a modified MTX/CCNU/procarbazine regimen using a higher dose of MTX (3g/m2), allowing 
cytotoxic MTX levels in the CSF and avoiding intrathecal therapy. Similar results compared to 
the EORTC regimen were obtained in terms of CR rate and OS. Subsequently, the same group 
added rituximab to their regimen and reported a higher CR rate (64%) and longer PFS (median 
of 16 months), but these numbers did not translate to an improved OS [30]. Altogether, the 
combination of HD-MTX, CCNU, procarbazine (with or without rituximab) appears to be an 
active and relatively well tolerated regimen considering the premorbid characteristics of the 
elderly population. Another combination consisting of HD-MTX (3g/m2)  and temozolomide 
(TMZ)  (150-200 mg/m2) has been evaluated and reported comparable results to those of the 
EORTC regimen in terms of CR rate and PFS, except the longer OS observed which is most 
probably explained by a high rate of patients receiving salvage treatment at relapse [31]. Formal 
comparisons of different chemotherapy regimens have not been published. However,  in a 
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recently completed ANOCEF randomized phase II study which evaluated two HD-MTX-based 
polychemotherapy regimens, that is, MPV-A (HD-MTX, procarbazine, vincristine, cytarabine) 
and M-T (HD-MTX, TMZ),  the  toxicity was identical and all efficacy criteria (CR, PFS, OS) 
appeared better with MPV-A than with M-T although the differences were not significant [32].  
The G-PCNSL-SG-1 trial is the only completed phase III study in PCNSL. The results of this trial 
indicated that WBRT following HD-MTX-based chemotherapy has no impact on OS. The study 
was not specifically designed for elderly patients. However, 126 out of 526 eligible patients were 
70 years or older allowing for a detailed analysis of the characteristics of the elderly population. 
The overall response rate upon HD-MTX-based chemotherapy was significantly lower in the 
elderly. Furthermore, there was a higher rate of grade III/IV leukopenia in the elderly whereas 
acute toxicity was otherwise age-independent. PFS (4.0 versus 7.7 months) and OS (12.5 
versus 26.2 months), were significantly shorter and tumor recurrence after CR occurred 
dramatically earlier in elderly patients compared to the group of young patients (16.1 versus 
35.0 months) [19]. The latter indicates that elderly CR patients require consolidation and/or 
maintenance approaches which will need to be defined in the future. A randomized phase III 
trial comparing maintenance chemotherapy versus observation in this setting is currently 
planned in France. Reduced dose WBRT has been proposed as consolidation with a lowered 
risk of neurotoxicity [33]. However, only few elderly patients had a neuropsychological follow-up 
in this study (only 3 out of evaluated 12 patients were older than 60) and the benefit both in 
terms of efficacy and neurotoxicity particularly in this population is questionable [19, 34]. The 
CALGB50202 multicenter phase II trial reported promising results using high-dose cytarabine 
combined with etoposide as consolidation following a HD-MTX-based induction regimen. Of 
note, patients aged 60 years or older did as well as younger patients [35].  
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Regardless of age, no standard of care exists for patients with recurrent PCNSL. Randomized 
trials are lacking and the choice of therapy depends on various parameters such as the 
response to first-line treatment, time elapsed from last treatment, performance status and 
residual side-effects from previous therapies. Similar to the situation with newly diagnosed 
disease, higher age requires specific considerations with regard to co-morbidities, side-effects 
and interactions with other drugs. An analysis of patients treated within the G-PCNSL-SG1 trial 
indicates that elderly patients are treated less frequently and less aggressively at recurrence 
[19]. Re-challenge with HD-MTX-based regimens, radiation therapy – despite is unfavourable 
toxicity profile in elderly patients – and various chemotherapy agents such as temozolomide are 
among the available options which have been summarized elsewhere [36].  
 
Conclusions 
Elderly patients represent an important population of all PCNSL patients. Age has repeatedly 
shown to be a negative prognostic factor and the intense treatment regimens administered to 
young patients aiming at a cure are not suitable for the elderly. Up to now, only few trials 
dedicated to the specific needs of elderly PCNSL patients have been performed. Whenever 
possible, HD-MTX remains the backbone of any successful therapy in the elderly. However, 
similar to young patients, the value of combinatorial approaches with other drugs must be 
determined within clinical trials. The design of these studies must respect the specific needs of 
elderly patients including their increased risk of suffering from significant side effects. Treating 
as many patients as possible within such trials must be pursued to allow for optimized treatment 
regimens. 
 
 
Key points 
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• Age is an important treatment-independent prognostic factor in PCNSL patients 
• Elderly patients are at increased risk of suffering from severe side effects from WBRT 
and chemotherapy  
• HD-MTX should be administered to elderly patients whenever possible since convincing 
alternatives are lacking 
• The combination of HD-MTX and WBRT results in the development of dementia in the 
majority of elderly patients and must therefore be avoided 
• Future trials for elderly PCNSL patients must aim at defining more active regimens with 
good tolerability in order to preserve quality of life and autonomy 
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Table 1. Prospective trials using HD-MTX-based therapy in elderly patients  
 
 n Median age Treatment CR PR PFS OS 
Omuro et al, 2007 
[31] 23 68 MTX, temozolomide 55% 0% 8 35 
Hoang-Xuan et al, 
2003 [28] 
 
50 72 MTX, CCNU, procarbazine, prednisolone. MTX and cytarabine i.th. 42% 6 % 10.6 14.3 
Illerhaus et al, 
2009 [29] 
30 70 MTX, CCNU, procarbazine 44% 26% 5.9 15.4 
Fritsch et al, 
2011 [30] 
28 76 MTX, CCNU, procarbazine, rituximab 64% 18% 16 17.5 
Roth et al, 2012 [19] 126 73 
MTX, ifosfamide,  
+/- WBRT 
30% 14% 4.0 12.5 
Omuro et al, 2013 
[32] 95 73 
MTX, procarbazine, vincristine, cytarabine 
MTX, temozolomide 
62% 
45% 
26% 
20% 
9.5 
6.1 
31 
14 
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